Skip to main content
Home
  • AI Mode
  • Supply Chain Orchestration
    fast
    Supply Chain Orchestration
    • Life Sciences Company
    • Direct Material Supplier
    • Contract Manufacturer
    • Third Party Logistics
    • Wholesale Distributor
    • Healthcare Provider
    • Retail Pharmacy
  • Network
  • Products
    fast
    Products
    • Multienterprise Information Network Tower (MINT)
    • Process Orchestration for Empowered Teams (POET)
    • Track-and-Trace
  • Resources
    fast
    Resources
    • Resource Center
    • TraceLink University
    • Partners
    • Community
    • Events
  • About
    fast
    About
    • Our Story
    • Newsroom
    • Culture and Careers
    • Leadership
    • Our Values
    • Corporate Social Responsibility
    • Contact Sales
  • Log In
    • Tracelink Classic
      TraceLink Classic app.tracelink.com
      Redirect
    • Opus Platform
      Opus Platform opus.tracelink.com
      Redirect
Log In
  • Tracelink Classic
    TraceLink Classic app.tracelink.com
    Redirect
  • Opus Platform
    Opus Platform opus.tracelink.com
    Redirect
Resources

Breadcrumb

  1. Home
  2. Resources
  3. Resource Center

FDA Reiterates: No Extensions to the DSCSA Stabilization Period

banner-image
  • Download PDF
  • Share
    • LinkedIn
    • Facebook
    • Mail
    • Twitter

Table of contents

With the end of the DSCSA stabilization period drawing near, the FDA reiterated at the 2024 FDLI Annual Conference that there will be no extensions to the DSCSA stabilization period.

What does this mean for the pharmaceutical and healthcare industry? This article looks at the FDA’s recent remarks and how TraceLink can help you ensure you’re ready in time for the end of the DSCSA stabilization period on Nov. 27.
 

No more “kicking the can down the road”

At the 2024 Food and Drug Law Institute Annual Conference, the FDA’s Director of the Center for Drug Evaluation and Research (CDER) Patrizia Cavazzoni fielded questions on the U.S. Drug Supply Chain Security Act (DSCSA) and compliance timelines. She stressed that the FDA remains firm in its stance: the organization does not intend to extend the DSCSA stabilization period.

“I really want to emphasize that this is not really a matter of kicking the can down the road,” Cavazzoni said, as reported by Regulatory Focus. She further reaffirmed that pharmaceutical and healthcare companies should be using the extra 12 months afforded by the DSCSA stabilization period to finish troubleshooting their systems and processes for DSCSA compliance.

The FDA is in the process of finalizing its own preparations as well. Cavazzoni told the crowd that CDER’s NextGen Portal, a tool for communicating with the FDA for drug recalls and suspect product investigations, is currently live and will be ready to accept DSCSA-related compliance documents in November.

Subsequently, the FDA announced on June 13 that it would grant small dispensers exemptions from certain requirements until November 27, 2026. These exemptions only apply to certain requirements of section 582 of the FD&C Act, and only to dispensers with 25 or fewer full-time employees licensed as pharmacists or qualified as pharmacy technicians.
 

DSCSA: A lot to do and only a little time to do it

The implications of the FDA’s recent statements are clear: all companies in the pharmaceutical supply chain barring small dispensers must have DSCSA-compliant processes and systems operational by November. Those that aren’t ready may face regulatory fines in addition to other complications such as product shortages, operational disruption, and trade partner penalties.

While many companies in the pharmaceutical and healthcare industry have at least begun their DSCSA compliance efforts, the reality is that the scope of technical and operational change required by DSCSA is extensive. Even those that have addressed the technical requirements of DSCSA and are able to electronically exchange EPCIS with their trade partners will still need a plan for things like:

  • DSCSA scalability testing: What scalability testing have you completed with your trade partners?  Are their systems capable of receiving the standard EPCIS messages describing 100’s, 1000’s or 100,000’s of your products? If your customers are not able to process transactions at scale, acceptance of your product may be at risk.  
  • DSCSA exceptions: There will be an influx of compliance-related exceptions as the industry gets accustomed to sending EPCIS in a live environment. Do you have the capabilities to resolve these exceptions with your trade partners quickly so they don’t disrupt your sending and receiving processes?
  • DSCSA standard operating procedures (SOPs): What are your processes for inspecting product identifiers? Do you have systems in place for storing product tracing data in compliance with the DSCSA? What happens when trade partners send a suspect or illegitimate product notification?

DSCSA touches several areas of operations and there is not a lot of time to prepare—Nov. 27 is less than 173 days away. Will you be ready in time?
 

TraceLink offers the fastest path to DSCSA compliance

The good news is that no matter where you are in your DSCSA compliance project, you can still achieve compliance before the end of the DSCSA stabilization period. However, you do need to act quickly.  Companies should expect a surge in activity as the deadline nears, making it more difficult for your partners to respond to everyone in a timely manner.  

TraceLink offers the fastest, lowest-risk and lowest cost of ownership to achieving DSCSA compliance by Nov. 27. Our network-based approach to integration enables companies to connect with hundreds or even thousands of trade partners through a single integration to the TraceLink network, after which you can begin exchanging serialized T2 product data in compliance with the DSCSA. To date, TraceLink has implemented more than 5,500 DSCSA transaction integrations, with more than 2 million DSCSA EPCIS transactions exchanged in the last two months alone.

In addition to enabling the electronic exchange of EPCIS, TraceLink’s network solution also provides capabilities for accelerating and simplifying processes surrounding DSCSA. This includes working with end-to-end trade partners to resolve compliance exceptions through a single shared application and streamlining product verification with a comprehensive interoperable lookup directory.

All of these processes and capabilities are supported by TraceLink’s resilient and adaptable network architecture. The TraceLink network is continually maintained by our internal team on your behalf, so you never have to worry about managing integrations or updating your software to accommodate standards changes. TraceLink also has well over 200 people on our support team, ready to assist with and troubleshoot any obstacles encountered on your path to DSCSA compliance.

TraceLink is happy to review your DSCSA project ahead of Nov. 27. If you’re using a competitor’s solution, it’s not too late to switch—just fill out this form and we’ll get in touch promptly to assess your requirements. If you’re a TraceLink customer with any questions, contact your account executive for a deeper discussion on your implementation. 

 

BlogUS Drug Supply Chain Security ActDSCSA for Dispensers, DSCSA for Manufacturers

Table of contents

Contact TraceLink to review your DSCSA strategy!
Fill out the form to schedule a review now.
 

Thank you for contacting us; we’ll be in touch shortly.

Related Content
Supply chain performance
Drop Shipments, 340B, and Returns: Unpacking the Complexity of Shipments Under DSCSA
The U.S. DSCSA creates new logistical challenges for drop shipments, 340B and returns. See why a network-based platform is key to addressing these obstacles.
View More
Healthcare-Pharmacy
How to Automate Compliance Exception Management During the DSCSA Stabilization Period
DSCSA compliance exceptions are on the rise. Learn how to digitalize and automate exception management to resolve exceptions faster.
View More
network
DSCSA 2023 Compliance for Drug Manufacturers Solution Brief
DSCSA 2023 introduces significant regulatory compliance challenges and new operational complexities for drug manufacturers.
View More

Cookie Settings

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies or similar tracking technologies. Please see below for an overview of the categories of cookies and similar technologies used on this site. You can allow or deny some of all of them, except Strictly Necessary Cookies which are required to provide the site to you. However, blocking some types of cookies may impact your experience of the site and services we are able to offer.

Please see our Cookie Policy for more details, including a list of the cookies we use. You can change your consent options at any time by following the “Cookie Settings” link in the Cookie Policy.
'Strictly Necessary' cookies let you move around the Site and use essential features like secure areas, shopping baskets and online billing. Without these cookies you would not be able to navigate between pages or use certain vital features of our Site, so we do not require your consent for their use. These cookies don't gather any information about you that could be used for marketing or remembering where you've been on the internet. For example, we use these Strictly Necessary cookies to identify you as being logged in to the Site. You can set your browser to block or alert you about these cookies, but if you do so, some parts of the Site will not work.
'Performance' cookies collect information about how you use the Site, such as which pages you visit, the time spent on the Site and if you experience any errors. We use performance cookies to provide aggregated statistics on how the Site is used and help us improve the Site including by measuring any errors that occur.
'Functional' cookies are used to provide services or to remember settings to improve your visit. We use 'Functionality' cookies to remember your settings and choices and show you when you're logged in to the Site.
‘Targeting' cookies are linked to services provided by third parties, such as 'Like' buttons and 'Share' buttons. The third party provides these services in return for recognizing that you have visited the Site. We also use 'Targeting' cookies to gather information that could be used to display content that we think may interest you.

Footer

  • Quick Links
    Get a Demo
    TraceLink Network Directory
    The Network
    OPUS Platform
    Technical Support
    Open Jobs
    API: Terms of Use
  • Products
    Multienterprise Information Network Tower
    U.S. DSCSA Compliance
    Targeted Recalls
    Process Orchestration for Empowered Teams
    Serialization
    Global Compliance
  • Resources
    Resource Center
    Events
    TraceLink University
    Partners
    Community
  • About TraceLink
    Our Story
    Newsroom
    Culture & Careers
    Leadership
    Our Values
    Corporate Social Responsibility
  • Hot Topics
    Transaction Integration
    Supply Chain Visibility
    DSCSA Compliance
    Process Orchestration
    Kazakhstan Compliance for Pharmaceuticals
    Kyrgyzstan Compliance for Pharmaceuticals
Follow Us on Social
Facebook
Linkedin
X
Legal & Trust.
© TraceLink Inc. 2009-2026 All Rights Reserved
Contact Us Today
Contact us today to begin your journey toward agentic supply chain orchestration — digitalize your end-to-end supply chain with intelligence, flexibility, and collaborative orchestration.
Contact Us
Stay Up-to-Date
Subscribe to receive industry insights and stay at the forefront of evolving trends.
Subscribe